News

A 3-minute video and quick-reference list of October's 7 FDA cancer approvals, with the biomarker and monitoring points nurses need for each.

Oral vitamin C did not slow clonal growth in the phase 2 EVITA trial but was linked to longer survival.

Sylvester's Nicole Doell, MSN, RN, discusses how oncology nurses can support patients with breast cancer emotionally, from diagnosis to survivorship.

Kathryn Shady, PhD, RN, OCN, discusses research on emotional dissonance and vicarious trauma among hematology/oncology nurses.

Daraxonrasib, tarlatamab, an mRNA melanoma therapy and ivonescimab led ESMO 2026. Tell us which findings you can act on now.

At an Oncology Nursing News roundtable, APPs discussed earlier lifileucel referral, IL-2 dosing, and toxicities that emerge after discharge.

Suzanne E. Barron, CRNP, explains how education, premedication, and pharmacy coordination streamline intravesical gene therapy treatment days.

Leslie Smith, DNP, shares how nurses at any hospital can work around limited time, heavy workloads, and slow approvals to get involved in research.

At an ONN Case-Based Roundtable, APPs discussed when to raise TIL therapy in melanoma and how to prepare patients for lymphodepletion and IL-2.

At EONS 2026, a City of Hope nurse practitioner explains how shifting immunotherapy from infusion to injection can free nurse and chair time.

Dana-Farber nurse practitioners reflect on cross-country networking, resource gaps, and ADC education needs after JADPRO Live 2026.

An NP-led roundtable reviewed 3L+ trial data in metastatic colorectal cancer and shared nursing strategies for myelosuppression, dosing, and goals.

New ANA guidance sets shared duties for nurses, leaders, and educators and favors restorative responses over zero-tolerance policies.

In TALAPRO-3, adding talazoparib to enzalutamide cut the risk of radiographic progression or death by 52%; anemia was the leading toxicity.

A Fox Chase intervention raised trial-naïve patients' understanding of placebo use and randomization; its effect on enrollment is still untested.

Divarasib beat first-generation KRAS G12C inhibitors in NSCLC, while new data on olomorasib, daraxonrasib, and a KRAS G12D inhibitor expand the field.

Yingzi Zhang, PhD, RN, discusses anxiety and depression data from 21,206 oncology patients ahead of the ANE Research Symposium.

Stepped care for fear of cancer recurrence was rated feasible by most clinicians, while training all staff to screen was rated least feasible.

A breast surgeon explains how nurses can build baseline bioimpedance screening and long-term lymphedema surveillance into clinic workflows.

Oncology nurses play a key role guiding patients about AI breast cancer risk assessment tools, dynamic re-testing, and individualized screening plans.

Dana-Farber nurse practitioners outline ADC patient selection, sequencing, ILD surveillance, and patient education from JADPRO Live 2026.

Brianne Whitley, CNP, of Dana-Farber, shares strategies for hot flashes, sexual health, survivorship planning, and clinical trial access for men.

The approval covers IV and subcutaneous pembrolizumab and raises the TMB-H threshold from 10 to 13 mutations/megabase.

The oral, once-daily EGFR inhibitor is now in specialty distribution for patients whose disease progressed after platinum-based chemotherapy.

Explore how nurses support kidney transplant candidates diagnosed with renal cell carcinoma, covering early detection, treatment options, and care.

Dana-Farber's Brianne Whitley, CNP, details red-flag symptoms, ER-positive biology, and why every man with breast cancer needs a genetic referral.

European survey reveals how oncology nurses manage complex multiple myeloma care amid time and resource constraints.

Leslie Smith, DNP, discusses mediating trial care, vetting protocols for nursing scope of practice, and guiding frontline nurses toward research.